Celltrion Analysis Shows OMLYCLO Benefits Persist 16 Weeks After Treatment Ends

• Celltrion will present three post hoc analyses from a Phase 3 Omlyclo study at ACAAI on Nov. 14-15, 2026.
• Quality-of-life improvements preceded disease activity responses in chronic spontaneous urticaria, with treatment effects persisting up to 16 weeks following discontinuation.
• Omlyclo showed comparable efficacy to reference omalizumab regardless of baseline itch severity, with comparable pharmacokinetics in patients with comorbid asthma.
• The presentations follow October's US launch of Omlyclo, the first and only FDA-approved interchangeable biosimilar to Xolair.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN93602) on November 12, 2026, and is solely responsible for the information contained therein.